• Nua Surgical

  Participated · Series A · Dec 2024

  Nua Surgical develops SteriCISION, the first self-retaining retractor specifically designed for Caesarean-section (C-section) surgery. The patented, single-use sterile device is ergonomically designed to provide fast, adjustable and safe retraction, helping clinicians deliver the baby, repair tissue, and identify bleeds. The company positions SteriCISION to reduce surgical complications and lower healthcare costs for a procedure performed over 30 million times annually. Proceeds from the recent financing will fund regulatory clearance efforts, including steps toward FDA clearance, and support early commercialization. Nua Surgical plans to expand its team and establish manufacturing in Ireland as part of its next development phase. The company has backing from public and private investors and is moving from product development toward market entry.

• May Health

  Participated · Series B · May 2024

  May Health is a medical device company focused on expanding therapeutic options for women suffering from polycystic ovary syndrome (PCOS)-related infertility. Its lead product, the Anavi™ System, enables a one-time, office-based procedure intended to restore ovulation in patients who do not respond to, are contraindicated to, or decline first-line treatments. The device secured CE Mark certification under EU MDR in October 2025 and is currently being evaluated in the U.S. REBALANCE pivotal IDE trial across more than 15 fertility centers. By targeting a condition that affects an estimated 10–13% of reproductive-age women worldwide, the company addresses a significant unmet clinical need. Management is advancing toward FDA marketing authorization while simultaneously preparing for commercialization in Europe and the United States. Backed by a syndicate of life-science investors, May Health is capitalizing on strategic partnerships to accelerate clinical development and future market launch.

• Cambrios Technologies

  Participated · Series D · Nov 2009

  Cambrios develops ClearOhm, a silver nanowire-based transparent conductor that the company says offers higher optical and electrical performance than traditional materials such as indium tin oxide (ITO). ClearOhm ink is used to produce high-performance transparent conductive films for touch panels, displays, OLED lighting tiles, EMI shielding, ePaper and thin-film photovoltaics. The company reports recent commercial success and positions silver nanowires as the technology of choice to replace ITO in the display industry. Cambrios announced a $10M strategic investment from Samsung Venture Investment Corporation to help fuel growth and reinforce its market position. Samsung’s shareholding is described as supporting Cambrios’ ability to serve customers better and drive adoption of silver-nanowire displays and lighting. The company is headquartered in Sunnyvale, Calif., with offices in Japan and Taiwan. Cambrios Technologies Corporation develops nanotechnology-based transparent conductors marketed as ClearOhm™ for electronic devices. ClearOhm™ is sold as a coating for plastic or glass, as deposited film on PET and other substrates, or as a transfer film, and the company positions it as having superior optical and electrical performance to indium tin oxide. Applications cited include touch screens, liquid crystal displays, e-paper, OLED devices, OLED lighting and thin-film photovoltaics, and the company targets touch, display, photovoltaic and lighting consumer-electronics markets. Cambrios intends to accelerate product introductions and commercial growth across multiple consumer electronic device markets and to deepen collaboration with Samsung Group companies. Leadership was updated with John LeMoncheck named President and CEO and founding CEO Dr. Michael R. Knapp becoming Chairman. The company is based in Sunnyvale, Calif. Cambrios Technologies Corporation, based in Sunnyvale, CA, develops proprietary products using nanotechnology to simplify electronics manufacturing processes and improve end-product performance. The company works with strategic partners and distributors to commercialize its offerings for electronics and display manufacturers. Recently Cambrios completed the first closing of its Series D financing, reflecting continued institutional support. Strategic corporate relationships include Sumitomo Corporation (its Japan and Taiwan distributor), Chisso Corporation (a commercialization partner for LCD manufacturers) and Nissha Printing Co. Ltd. (a large touch‑screen manufacturer). Company leadership emphasized strong investor belief in the company’s progress and a mutual commitment to achieving collaborative business goals.

No current team members are available.